Antiprotozoal drugs: challenges and opportunities

References

• Lax G, Lee WJ, Eglit Y, et al. Ploeotids represent much of the phylogenetic diversity of euglenids. Protist. 2019;170(2):233–257.
   PubMed Web of Science ®Google Scholar
• Cavalier-Smith T, Chao EE, Snell EA, et al. Multigene eukaryote phylogeny reveals the likely protozoan ancestors of opisthokonts (animals, fungi, choanozoans) and amoebozoa. Mol Phylogenet Evol. 2014;81:71–85.
   PubMed Web of Science ®Google Scholar
• Vermelho AB, Supuran CT. Antiprotozoal drug development and delivery. Cham Switzerland: Springer Nature; 2022. p. 1–330.
   Google Scholar
• Vermelho AB, Rodrigues GC, Supuran CT. Why hasn’t there been more progress in new Chagas disease drug discovery? Expert Opin Drug Discov. 2020;15(2):145–158.
   PubMed Web of Science ®Google Scholar
• Debnath A. Drug discovery for primary amebic meningoencephalitis: from screen to identification of leads. Expert Rev Anti Infect Ther. 2021;19(9):1099–1106.
   PubMed Web of Science ®Google Scholar
• Kofman A, Guarner J, Humphries RM. Free living amoebic infections: review. J Clin Microbiol. 2022;60(1):e0022821.
   PubMedGoogle Scholar
• Vermelho AB, Mori M, Donald WA, et al. Challenges and promises for obtaining new antiprotozoal drugs: what’s going wrong? In: Vermelho A Supuran C, editors. Antiprotozoal drug development and delivery. Cham Switzerland: Springer Nature; 2022. p. 321–330.
   Google Scholar
• Consalvi S, Tammaro C, Appetecchia F, et al. Malaria transmission blocking compounds: a patent review. Expert Opin Ther Pat. 2022;32(6):649–666.
   PubMed Web of Science ®Google Scholar
• Krungkrai J, Prapunwatana P, Wichitkul C, et al. Molecular biology and biochemistry of malarial parasite pyrimidine biosynthetic pathway. Southeast Asian J Trop Med Public Health. 2003;34(2):32–43.
   PubMedGoogle Scholar
• Müller J, Hemphill A. In vitro culture systems for the study of apicomplexan parasites in farm animals. Int J Parasitol. 2013;43(2):115–124.
   PubMed Web of Science ®Google Scholar
• Wang B, Castellanos-Gonzalez A, AC W Jr. Novel drug targets for treatment of cryptosporidiosis. Expert Opin Ther Targets. 2020;24(9):915–922.
   PubMed Web of Science ®Google Scholar
• Pessanha de Carvalho L, Kreidenweiss A, Held J. Drug repurposing: a review of old and new antibiotics for the treatment of malaria: identifying antibiotics with a fast onset of antiplasmodial action. Molecules. 2021;26(8):2304.
   PubMed Web of Science ®Google Scholar
• Vallejo M, Reyes PP, Martinez Garcia M, et al. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database Syst Rev. 2020 Dec 11;12(12):CD004102.
   PubMedGoogle Scholar
• de Araújo RV, Santos SS, Sanches LM, et al. Malaria and tuberculosis as diseases of neglected populations: state of the art in chemotherapy and advances in the search for new drugs. Mem Inst Oswaldo Cruz. 2020;115:e200229.
   PubMed Web of Science ®Google Scholar
• Roatt BM, de Oliveira Cardoso JM, De Brito RCF, et al. Recent advances and new strategies on leishmaniasis treatment. Appl Microbiol Biotechnol. 2020;104(21):8965–8977.
   PubMed Web of Science ®Google Scholar
• Mansoldo FRP, Carta F, Angeli A, et al. Chagas disease: perspectives on the past and present and challenges in drug discovery. Molecules. 2020;25(22):5483.
   PubMed Web of Science ®Google Scholar
• Wall RJ, Rico E, Lukac I, et al. Clinical and veterinary trypanocidal benzoxaboroles target CPSF3. Proc Natl Acad Sci U S A. 2018;115(38):9616–9621.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Supuran CT, Winum JY. Benzoxaborole compounds for therapeutic uses: a patent review (2010- 2018). Expert Opin Ther Patents. 2018 Jun;28(6):493–504.
   PubMed Web of Science ®Google Scholar
• Bonardi A, Nocentini A, Cadoni R, et al. Benzoxaboroles: new potent inhibitors of the carbonic anhydrases of the pathogenic bacterium vibrio cholerae. ACS Med Chem Lett. 2020;11(11):2277–2284.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Cadoni R, Dumy P, et al. Carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani chagasi are inhibited by benzoxaboroles. J Enzyme Inhib Med Chem. 2018;33(1):286–289.
   PubMed Web of Science ®Google Scholar
• Alterio V, Cadoni R, Esposito D, et al. Benzoxaborole as a new chemotype for carbonic anhydrase inhibition. Chem Commun (Camb). 2016;52(80):11983–11986.
   PubMed Web of Science ®Google Scholar
• Mazzeti AL, Capelari-Oliveira P, Bahia MT, et al. Review on experimental treatment strategies against trypanosoma cruzi. J Exp Pharmacol. 2021 Mar 31;13:409–432. DOI:10.2147/JEP.S267378.
   PubMedGoogle Scholar
• Pestana Caroli A, Mansoldo FRP, Cardoso VS, et al. Are patents important indicators of innovation for chagas disease treatment? Expert Opin Ther Pat. 2023;33:1–17. this issue. DOI:10.1080/13543776.2023.2176219.
   PubMedGoogle Scholar
• Verdan M, Taveira I, Lima F, et al. Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022). Expert Opin Ther Pat. 2023;33: this issue.
   Google Scholar
• Lopes EA, Santos MMM, Mori M. Anti-malaria drugs: what’s new in the patents? Expert Opin Ther Pat. 2023;33:in press (this issue).
   Google Scholar
• Quagliata M, Papini AM, Rovero P. Malaria vaccines. Expert Opin Ther Pat. 2023;33:1–10. in press (this issue). DOI:10.1080/13543776.2023.2190884.
   PubMedGoogle Scholar
• Capasso C, Supuran CT. The management of babesia, amoeba and other zoonotic diseases provoked by protozoa. Expert Opin Ther Pat. 2023;33:in press (this issue).
   Google Scholar
• Francesca A, Granese A, Guglielmi P. Novel therapeutic opportunities for Toxoplasma gondii, Trichomonas vaginalis and Giardia intestinalis infections. Expert Opin Ther Pat. 2023;33:in press (this issue).
   Google Scholar
• Melfi F, Carradori S, Campestre C, et al. Emerging compounds and therapeutic strategies to treat infections from trypanosoma brucei: an overhaul of the last 5-years patents. Expert Opin Ther Pat. 2023;33:1–17. in press (this issue). DOI:10.1080/13543776.2023.2193328.
   PubMedGoogle Scholar
• Mori M, Capasso C, Carta F, et al. A deadly spillover: sARS-CoV-2 outbreak. Expert Opin Ther Pat. 2020;30(7):481–485.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Coronaviruses. Expert Opin Ther Pat. 2021;31(4):291–294.
   PubMed Web of Science ®Google Scholar